In contrast to conventional gene therapy vectors, human artificial chromosomes (HACs) are episomal vectors that can carry large regions of the genome containing regulatory elements. So far, HACs have not been used as vectors in gene therapy for treating genetic disorders. Here, we report the amelioration of the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD) using a combination of HAC-mediated gene replacement and transplantation with blood vessel-associated stem cells (mesoangioblasts). We first genetically corrected mesoangioblasts from dystrophic mdx mice with a HAC vector containing the entire (2.4 Mb) human dystrophin genetic locus. Genetically corrected mesoangioblasts engrafted robustly and gave rise to many dystrophin-positive muscle fibers and muscle satellite cells in dystrophic mice, leading to morphological and functional amelioration of the phenotype that lasted for up to 8 months after transplantation. Thus, HAC-mediated gene transfer shows efficacy in a preclinical model of DMD and offers potential for future clinical translation.

Stem cell–mediated transfer of a human artificial chromosome ameliorates muscular dystrophy / F.S. Tedesco, H. Hoshiya, G. D’Antona, M.F.M. Gerli, G. Messina, S. Antonini, R. Tonlorenzi, S. Benedetti, L. Berghella, Y. Torrente, Y. Kazuki, R. Bottinelli, M. Oshimura, G. Cossu. - In: SCIENCE TRANSLATIONAL MEDICINE. - ISSN 1946-6234. - 3:96(2011 Aug 17), pp. 96ra78.1-96ra78.13. [10.1126/scitranslmed.3002342]

Stem cell–mediated transfer of a human artificial chromosome ameliorates muscular dystrophy

G. Messina;Y. Torrente;G. Cossu
2011

Abstract

In contrast to conventional gene therapy vectors, human artificial chromosomes (HACs) are episomal vectors that can carry large regions of the genome containing regulatory elements. So far, HACs have not been used as vectors in gene therapy for treating genetic disorders. Here, we report the amelioration of the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD) using a combination of HAC-mediated gene replacement and transplantation with blood vessel-associated stem cells (mesoangioblasts). We first genetically corrected mesoangioblasts from dystrophic mdx mice with a HAC vector containing the entire (2.4 Mb) human dystrophin genetic locus. Genetically corrected mesoangioblasts engrafted robustly and gave rise to many dystrophin-positive muscle fibers and muscle satellite cells in dystrophic mice, leading to morphological and functional amelioration of the phenotype that lasted for up to 8 months after transplantation. Thus, HAC-mediated gene transfer shows efficacy in a preclinical model of DMD and offers potential for future clinical translation.
skeletal-muscle; MDX mice; gene delivery; therapy; expression; mutations; mouse; CDNA
Settore BIO/17 - Istologia
17-ago-2011
Article (author)
File in questo prodotto:
File Dimensione Formato  
Sci Transl Med-2011-Tedesco-2011.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 2.79 MB
Formato Adobe PDF
2.79 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/170081
Citazioni
  • ???jsp.display-item.citation.pmc??? 86
  • Scopus 124
  • ???jsp.display-item.citation.isi??? 114
social impact